3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Classical hematology
18
Plasma cell
5
Other hematologic neoplasm
3
Gastrointestinal
3
Lymphoid
2
Sarcoma
1
Myeloid
1
Head & Neck
1
Genitourinary
1
CNS
1
Conditions
Venous Thromboembolism
1
Glioma
1
Glioblastoma
1
Astrocytoma
1
Interventions
Temozolomide
610
Radiotherapy
387
Bevacizumab
253
Magnetic Resonance Spectroscopy
202
Cyclophosphamide
177
Carboplatin
159
Radiosurgery
145
Etoposide
132
Radiation
120
Irinotecan
115
Vincristine
114
Cisplatin
102
Filgrastim
100
Specimen Handling
88
Nivolumab
87
pembrolizumab
81
Lomustine
80
Topotecan
73
Surgical Procedures, Operative
73
Doxorubicin
60
Melphalan
59
Carmustine
57
sargramostim
53
Radiotherapy, Intensity-Modulated
53
Isotretinoin
53
Peripheral Blood Stem Cell Transplantation
52
Granulocyte Colony-Stimulating Factor
50
Erlotinib Hydrochloride
50
Everolimus
48
Chemotherapy, Adjuvant
48
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
apixaban
×
CNS
×
Clear all
NCT05683808
2026-01-30
VTE-POG
University of Vermont Medical Center
Phase 2
Recruiting
40 enrolled